Butyrate Amide Derivatives for Palatable Oral Administration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current butyrate-based products face challenges due to their unpleasant taste and odor, poor palatability, and stability issues, making oral administration difficult, especially for pediatric patients, and limiting their use in long-term treatments.
Innovation Solution
Development of amide derivatives of short-chain fatty acids, particularly butyric acid, using biocompatible molecules like phenylalanine, which are odorless, tasteless, and stable, allowing for prolonged release in the intestine and improved solubility, such as phenylalanine-butyramide (FBA), facilitating easier oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If butyrate-based products are used for oral administration, then therapeutic efficacy is achieved, but unpleasant taste and odor reduce palatability
Solution Approach 1:
The patent uses amide derivatives as intermediary compounds that do not directly interact with taste buds but are metabolized in the intestine to release butyrate. This mediator approach eliminates the unpleasant taste and odor issues while preserving the therapeutic efficacy of butyrate in treating intestinal disorders.
Solution Approach 2:
The patent changes the chemical parameters of butyrate by converting it into amide derivatives with different molecular structures. This parameter transformation modifies the organoleptic properties (taste and odor) while maintaining the core therapeutic functionality through intestinal metabolism.
2Reliability
If butyrate-based products are used for oral administration, then therapeutic benefits are obtained, but stability issues limit long-term use
Solution Approach 1:
The patent performs preliminary chemical modification of butyrate into stable amide derivatives before administration. This preliminary action protects the active ingredient from degradation during storage and transport, ensuring stability while maintaining therapeutic benefits through controlled release in the intestine.
Solution Approach 2:
The patent creates composite molecular structures by combining butyrate with amino acid derivatives to form amide compounds. This composite approach enhances stability properties while preserving the therapeutic functionality of the butyrate component.
3Ease of operation
If amide derivatives are developed to improve palatability, then oral administration becomes easier, but synthesis complexity increases
Solution Approach 1:
The patent segments the synthesis process into distinct stages: first forming the amide bond between butyrate and amino acid derivatives, then purifying the intermediate products, and finally formulating the stable derivatives for administration. This segmentation makes the complex synthesis more manageable and industrially viable.
4Reliability
If butyrate is administered orally, then intestinal therapeutic effects are achieved, but poor solubility limits bioavailability
Solution Approach 1:
The patent changes the physical-chemical parameters of butyrate by converting it into amide derivatives with improved solubility characteristics. This parameter modification enhances bioavailability and intestinal absorption while maintaining the therapeutic effects on intestinal disorders.
Data Source
AI summary
The invention relates to novel derivatives of short-chain fatty acids, in particular derivatives of butyric acid, useful for all the known clinical applications of the latter, which show physicochemical characteristics suitable for an easy oral administration, being devoid of the unpleasant organoleptic properties that characterize butyrate. The new compounds are amide derivatives which can be synthesized by reaction of the corresponding fatty acid halide with a naturally occurring amino acid, phenylalanine or a suitable derivative thereof, and which are in a poorly hygroscopic, easily weighable form, stable to acids and alkalis and able to release the acid at the small and large bowel level in a constant manner over time. They do not have disagreeable odors and are practically tasteless, thus allowing the manufacture of preparations for oral administration also suitable for the therapy of chronic diseases and in the pediatric field.